Grifols discloses transfers of value made to European healthcare professionals

5 July 2022

In line with its commitment to transparency, Spanish plasma-derived medicines company Grifols (ME: GRF) has disclosed for the seventh consecutive year all payments and other transfers of value related to medicines and medical technology made to healthcare professionals and healthcare organizations in the several European countries listed within the European Federation of Pharmaceutical Industries and Associations’ (EFPIA) scope, including Spain.

In 2021, Grifols made transfers of value in Europe amounting to 18.9 million euros ($19.7 million). This 41% increase compared to 2020 is mainly due to two factors:

Larger investments in studies related to, among other areas, the SARS-CoV-2 virus, which resulted in a 38% increase in transfers of value related to R&D compared to 2020. They amounted to 15.6 million euros, representing 83% of the total.
The progressive recovery of face-to-face interactions with healthcare organizations and healthcare professionals at scientific events, which have returned to similar pre-pandemic levels.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK